RDHL

MKT CAP:$3M

RedHill Biopharma Ltd.

Market Cap

$3M

Healthcare·Drug Manufacturers - Specialty & Generic·🇮🇱 Israel·NASDAQ

Healthcare·Drug·🇮🇱·NASDAQ

Stock Price

$0.85-$0.18 (-17.81%)

Apr 22, 2026

Company Details

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chr...

CEO

Dror Ben-Asher

IPO Date

Jan 7, 2013

Website

www.redhillbio.com

Key Metrics TTM

Revenue

$10M

+157.6% YoY

Net Income

-$9M

EPS (Diluted)

-$4.00

Free Cash Flow

-$8M

Revenue / Share

$5.30

Gross Margin

64.5%

Operating Margin

-110.4%

Net Margin

-97.5%

FCF Margin

-86.0%

P/S

0.4x

P/E

—

Earnings Reports

Q2 2025

Sep 5, 2025

$2M+58.6%EPS -$1.00

Q1 2025

Apr 10, 2025

$2M+58.6%EPS -$1.00

FY 2024

Apr 10, 2025

$8M+23.2%EPS -$7.00

Q4 2024

Apr 10, 2025

$3M+382.0%EPS -$1.00

Q3 2024

Sep 30, 2024

$3M+382.0%EPS -$1.00

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 21	$22M	$11M	-$25M
Q3 21	$22M	$12M	-$17M
Q4 21	$22M	$3M	-$21M
Q2 22	$18M	$9M	-$9M
Q3 22	$18M	$8M	-$7M
Q4 22	$13M	$4M	-$10M
Q1 23	$4M	$2M	$29M
Q2 23	$2M	$990.0K	-$4M
Q3 23	$567.5K	$47.0K	-$6M
Q4 23	$567.5K	$47.0K	-$6M
Q1 24	$1M	$584.0K	-$4M
Q2 24	$1M	$584.0K	-$4M
Q3 24	$3M	$2M	-$3M
Q4 24	$3M	$2M	-$3M
Q1 25	$2M	$1M	-$2M
Q2 25	$2M	$1M	-$2M

Valuation

Quarter	P/S	P/E
Q2 21	7.8x	—
Q3 21	5.6x	—
Q4 21	3.4x	—
Q2 22	1.4x	—
Q3 22	1.2x	—
Q4 22	0.5x	—
Q1 23	0.6x	—
Q2 23	0.5x	1.4x
Q3 23	0.5x	0.3x
Q4 23	11.2x	3.0x
Q1 24	7.7x	—
Q2 24	6.3x	—
Q3 24	3.8x	—
Q4 24	2.1x	—
Q1 25	0.8x	—
Q2 25	0.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 21	-$19M	-$19M
Q3 21	-$19M	-$19M
Q4 21	-$15M	-$15M
Q2 22	-$17M	-$17M
Q3 22	-$6M	-$6M
Q4 22	-$2M	-$2M
Q1 23	-$7M	-$7M
Q2 23	-$11M	-$11M
Q3 23	-$9M	-$9M
Q4 23	-$9M	-$9M
Q1 24	-$3M	-$3M
Q2 24	-$3M	-$3M
Q3 24	-$2M	-$2M
Q4 24	-$2M	-$2M
Q1 25	-$3M	-$3M
Q2 25	-$3M	-$3M

Capital Expenditures

Quarter	CapEx
Q2 21	$3.0K
Q3 21	$21.0K
Q4 21	$3.0K
Q2 22	$163.0K
Q3 22	$22.0K
Q4 22	$1.3K
Q1 23	$0
Q2 23	$7.0K
Q3 23	$2.0K
Q4 23	$2.0K
Q1 24	$500
Q2 24	$500
Q3 24	$4.0K
Q4 24	$4.0K
Q1 25	$2.0K
Q2 25	$2.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 21	+2.9%	+38.9%
Q3 21	+3.2%	+10.2%
Q4 21	+2.8%	+3.9%
Q2 22	-10.8%	-29.0%
Q3 22	-18.4%	-46.8%
Q4 22	-40.8%	-41.7%
Q1 23	-83.7%	-159.6%
Q2 23	-90.2%	-77.4%
Q3 23	-96.8%	-73.3%
Q4 23	-95.6%	-71.0%
Q1 24	-64.3%	+121.6%
Q2 24	-28.4%	-11.2%
Q3 24	+382.0%	-11.7%
Q4 24	+382.0%	-11.7%
Q1 25	+58.6%	-23.3%
Q2 25	+58.6%	-23.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 21	$5M	24.5%
Q3 21	$2M	10.1%
Q4 21	$2M	8.5%
Q2 22	$618.0K	3.4%
Q3 22	$2M	9.2%
Q4 22	$1M	8.9%
Q1 23	$144.0K	4.0%
Q2 23	$705.0K	39.3%
Q3 23	$399.0K	70.3%
Q4 23	$399.0K	70.3%
Q1 24	$114.5K	8.9%
Q2 24	$114.5K	8.9%
Q3 24	$218.0K	8.0%
Q4 24	$218.0K	8.0%
Q1 25	$148.5K	7.3%
Q2 25	$148.5K	7.3%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q2 21	$10M	$10M	$15M
Q3 21	$6M	$8M	$16M
Q4 21	$6M	$51M	—
Q2 22	$1M	$8M	$9M
Q3 22	$2M	$7M	$7M
Q4 22	$1M	$33M	—
Q1 23	$1M	$6M	$5M
Q2 23	$1M	$4M	$5M
Q3 23	$598.5K	$3M	$3M
Q4 23	$598.5K	$3M	$3M
Q1 24	$329.5K	$3M	$2M
Q2 24	$329.5K	$3M	$2M
Q3 24	$464.5K	$2M	$1M
Q4 24	$464.5K	$2M	$1M
Q1 25	$482.0K	$2M	$1M
Q2 25	$482.0K	$2M	$1M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q3 21	$23M	$12M	$35M
Q4 21	$29M	$9M	$38M
Q1 22	$29M	$17.0K	$29M
Q2 22	$27M	$15.0K	$27M
Q3 22	$15M	$15.0K	$15M
Q4 22	$20M	$15.0K	$20M
Q1 23	$18M	$15.0K	$18M
Q2 23	$7M	$18.0K	$7M
Q3 23	$6M	$0	$6M
Q4 23	$6M	$0	$6M
Q1 24	$7M	$0	$7M
Q2 24	$7M	$0	$7M
Q3 24	$2M	$3M	$5M
Q4 24	$5M	$0	$5M
Q1 25	$3M	$0	$3M
Q2 25	$3M	$0	$3M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 21	93K	+8.7%	+30.5%
Q3 21	94K	+0.2%	+25.5%
Q4 21	100K	+6.7%	+30.0%
Q2 22	114K	+13.8%	+32.3%
Q3 22	128K	+12.3%	+36.8%
Q4 22	186K	+46.0%	+99.2%
Q1 23	195K	+4.5%	+95.1%
Q2 23	315K	+61.9%	+177.5%
Q3 23	548K	+73.8%	+329.3%
Q4 23	781K	+42.5%	+319.0%
Q1 24	2M	+201.2%	+1107.4%
Q2 24	2M	0.0%	+645.9%
Q3 24	3M	+9.6%	+370.1%
Q4 24	3M	0.0%	+230.0%
Q1 25	2M	-30.0%	-23.3%
Q2 25	2M	0.0%	-23.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 21	$118.1K	182
Q3 21	$118.7K	182
Q4 21	$109.8K	201
Q2 22	$91.3K	201
Q3 22	$87.3K	201
Q4 22	$113.3K	113
Q1 23	$31.8K	113
Q2 23	$15.9K	113
Q3 23	$5.0K	113
Q4 23	$10.7K	53
Q1 24	$24.3K	53
Q2 24	$24.3K	53
Q3 24	$51.6K	53
Q4 24	$78.2K	35
Q1 25	$58.3K	35
Q2 25	$58.3K	35

Revenue / Employee